Vaxart, INC 8-K filings

Vaxart, Inc. announced the dosing of the first patient in the 10,000-participant portion of its Phase 2b clinical trial for its oral pill COVID-19 vaccine candidate, supported by up to $460.7 million in federal funding.

Vaxart has adjourned its 2025 annual meeting of stockholders to June 2, 2025, to allow stockholders additional time to vote on key proposals, including a potential reverse stock split.

Vaxart's board approved resolutions to narrow the proposed reverse split range and proposes reducing authorized shares to maintain its Nasdaq listing.

Vaxart announces BARDA approval to begin dosing in the 10,000-participant phase of its Phase 2b clinical trial for its oral COVID-19 vaccine candidate.

Vaxart announces the appointment of Jeroen Grasman as its new CFO, effective May 19, 2025, succeeding Phillip Lee, who is resigning.

Vaxart reports Q1 2025 financial results, highlights the resumption of its COVID-19 Phase 2b trial, progress in its norovirus vaccine program, and a new CFO appointment.

Vaxart is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting.

Vaxart provides an update on its vaccine programs, including the lifting of a government stop work order and progress in norovirus trials, while also emphasizing the importance of a reverse stock split to maintain its Nasdaq listing.

Vaxart's BARDA-funded project resumes after receiving a lift notice from Advanced Technology International (ATI), allowing the company to restart activities and discussions with BARDA.

Vaxart, Inc. has entered into an agreement to sell up to $50 million of its common stock through an at-the-market offering.

Vaxart reports its full year 2024 financial results, provides a business update, and highlights the initiation of a Phase 1 clinical trial for its second-generation oral norovirus vaccine.

Vaxart has commenced a Phase 1 clinical trial to evaluate its second-generation oral norovirus vaccine against its first-generation version, with topline data expected by mid-2025.

Vaxart, Inc. has been issued a stop work order by Advanced Technology International (ATI) for its BARDA-funded project, impacting all efforts except for the per protocol follow-up for the 400-person cohort.

Vaxart receives a $105.9 million funding boost from BARDA to advance its Phase 2b clinical trial of an oral COVID-19 vaccine candidate against an mRNA comparator.

Vaxart has appointed Kevin Finney, a seasoned biotech executive, to its Board of Directors, while Robert Yedid has resigned, both effective January 28, 2025.

Vaxart's COVID-19 vaccine Phase 2b trial is set to expand to 10,000 participants after a favorable safety review, while the company's norovirus program advances to Phase 1 and a new avian influenza vaccine candidate is in preclinical testing.

Vaxart has been granted an extension until June 30, 2025, to regain compliance with Nasdaq's minimum bid price requirement.

Vaxart has received an additional $37.7 million in funding for its Phase 2b trial of an oral COVID-19 vaccine, bringing the total trial funding to $134.2 million.

Vaxart has completed enrollment of the sentinel cohort in its Phase 2b clinical trial evaluating its oral COVID-19 vaccine candidate against an approved mRNA vaccine.

Vaxart reports its Q3 2024 financial results, highlighting progress in its COVID-19 vaccine trial and norovirus program, with a focus on completing the sentinel cohort enrollment and evaluating next steps for norovirus.

Vaxart has terminated its Controlled Equity Offering Sales Agreement, effective October 18, 2024, after selling 17.5 million shares for $28.6 million since September 2021.

Vaxart has received increased funding and commenced the sentinel phase of its Phase 2b trial for an oral COVID-19 vaccine, comparing it to an approved mRNA vaccine.

Vaxart announced a significant BARDA contract of up to $453 million to support a Phase 2b trial for its oral COVID-19 vaccine, alongside positive Phase 1 data for its norovirus vaccine and an extended cash runway.

Vaxart has received a notice from Nasdaq for not meeting the minimum bid price requirement of $1.00 per share, placing its listing status at risk.

Vaxart has amended its previous 8-K filing to correct a calculation error in the voting results for a proposal to increase the company's authorized shares, although the outcome of the vote remains unchanged.

Vaxart announces a significant BARDA award and a $40 million offering, extending its cash runway into 2026 and supporting key clinical programs.

Vaxart, Inc. has announced a $40 million underwritten offering of 50 million shares of its common stock at a price of $0.80 per share.

Vaxart has been awarded up to $453 million by BARDA to conduct a Phase 2b trial comparing its oral COVID-19 vaccine pill against an approved mRNA vaccine.

Vaxart's stockholders approved an increase in authorized shares and amendments to the company's equity incentive and employee stock purchase plans at the 2024 annual meeting.

Vaxart reports positive Phase 1 norovirus trial results in lactating mothers and anticipates initiating a Phase 2b COVID-19 vaccine study in the second quarter of 2024.